BJD

•    Review on revised guidelines from AAO (2016) on retinal screening for patients on hydroxychloroquine

http://onlinelibrary.wiley.com/doi/10.1111/bjd.15567/full

•    immune checkpoint inhibitors causing alopecia areata

- Immune checkpoint inhibitors produce various immune-related adverse events including alopecia, with an incidence ranging from 1·0% to 2·0%.

- The associated clinical and histological findings and responses to treatment with immune checkpoint inhibitor-induced alopecia has not previously been characterized.

What does this study add? 

- Immune checkpoint inhibitors may be associated with alopecia, and clinical and histological findings are consistent with alopecia areata.
- Knowledge and recognition of this type of alopecia is critical for counselling and early intervention in order to maintain optimal health-related quality of life in patients.

http://onlinelibrary.wiley.com/doi/10.1111/bjd.15591/full
http://onlinelibrary.wiley.com/doi/10.1111/bjd.15237/full

•    short case report of refractory AU treated with oral tofacitinib and IL triamcinolone
http://onlinelibrary.wiley.com/doi/10.1111/bjd.15483/full

CED

•    intraoperative dermoscopic features of onychomatricoma
http://onlinelibrary.wiley.com/doi/10.1111/ced.13077/full

•    Role of nail bed methotrexate injections in isolated nail psoriasis: conventional drug via an unconventional route 
http://onlinelibrary.wiley.com/doi/10.1111/ced.13087/full

JAAD

•    Nail involvement in systemic sclerosis
http://www.jaad.org/article/S0190-9622(16)31111-2/fulltext

•    Erosive pustular dermatosis of the scalp
http://www.jaad.org/article/S0190-9622(16)31240-3/fulltext

•    Histology FFA vs LPP – depth of inflammation
http://www.jaad.org/article/S0190-9622(16)30903-3/fulltext

•    Hypopigmentation FFA 
http://www.jaad.org/article/S0190-9622(17)30001-4/fulltext

•    Hydroxychloroquine screening receommendations

Hydroxychloroquine has unique immunomodulatory properties and an attractive adverse effect profile.

Over the past 10 years, research has led to significant updates in clinical recommendations concerning the optimal use of hydroxychloroquine and monitoring of patients taking it. We discuss updated recommendations concerning hydroxychloroquine daily dosing, retinopathy screening, serologic monitoring, use in smokers, use in pregnant women, and adverse effect risk and monitoring. This review can hopefully serve as an aid to dermatologists and help ensure they continue using hydroxychloroquine safely and effectively. (J Am Acad Dermatol 2017;76:1176-82.) 
http://www.jaad.org/article/S0190-9622(17)30022-1/fulltext

JAMA Derm

•    Treatment of alopecia areata with tofacitinib

Tofacitinib citrate is a Janus kinase 1/3 inhibitor approved for the treatment of rheumatoid arthritis, but it has recently been used to treat alopecia areata (AA).1- 3 In this study, investigators searched the medical records of the Cleveland Clinic for any patients with confirmed AA who were treated with oral tofacitinib (Xeljanz; Pfizer) using a standardized, systematic treatment regimen. 13 patients were identified and 7 had regrowth of >50%.

http://click.alerts.jamanetwork.com/click/h1x4t-b0a25q-4iutc8e5/

JEADV

•    Dyslipidaemia in androgenetic aloepcia
http://onlinelibrary.wiley.com/doi/10.1111/jdv.14308/full

•    Nail psoriasis severity index in MARCOPOLO trial of ustekinumab
http://onlinelibrary.wiley.com/doi/10.1111/jdv.14083/full

•    Diagnosis of scalp aplasia cutis with ultrasound 
http://onlinelibrary.wiley.com/doi/10.1111/jdv.14018/full

JID
•    nil